Your Search Returned 446 tagged news reports
08pm EDT William Ackman, CEO of Pershing Square Capital Management, speaks at the Partner Connect 2013 conference, sponsored by Thomson Reuters, in Boston April 5, 2013. Activist investor William Ackman, who is betting more than $1 billion that
ET A sizable investor in Allergan Inc. doesn't favor the offer Valeant Pharmaceuticals International Inc. has made for the Botox maker, in conjunction with activist William Ackman. Dan Davidowitz, the chief investment officer of Polen Capital
It's a monster deal with a fair amount of complication and $45 billion on the line hedge-fund manager Bill Ackman is teaming up with pharmaceutical company, Valeant (VRX), to acquire one of its competitors, Botox-maker Allergan (AGN). Together, they
Allergan Inc. , the Irvine company that makes Botox, has adopted a "poison pill" defense that could make it more difficult for Canadian company Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman to force through a takeover
Coming in after the closing bell. "People ( including ourselves ) are getting impatient with Apple and Tim Cook," BI's Jay Yarow says. "Apple's revenue growth has cratered and is now expected to be flat compared to a year-ago's sales." Read our full
There've been mixed fortunes for three of Europe's biggest drugmakers. David Pollard looks at the issues they are facing and the impact from generic brands and emerging markets. Reuters Europe Billionaire investor William Ackman is stepping up his
Bill Ackman has been paying a former Herbalife executive to the government and media information on the company's activities, ABC news reports...The hedge fund manager has said that he will stop at nothing to see multi-level marketing firm Herbalife'
Novartis deals. Swiss drug giant Novartis has essentially swapped its vaccine business, worth $7.1 billion plus royalties, for the rights to GSK's oncology products, for which it paid $14.5 billion. Reuters says Novartis is trying to simplify its
Earlier today, Swiss drugmaker Novartis announced three huge deals : 1) it's acquiring GlaxoSmithKline's oncology business for $14.5 billion; 2) it's divesting its vaccines business to GSK for $7.1 billion plus royalties; and 3) it's divesting its
Bausch & Lomb eye care products on display at Maximart Pharmacy in Palo Alto, Calif., on May 16, 2007. Valeant Pharmaceuticals Inc. has confirmed it's buying Bausch + Lomb Holdings in a US$8.7-billion cash deal that will boost the Canadian drug maker'